In November 2007, Shinya Yamanaka, MD, PhD, senior investigator at Gladstone Institutes, demonstrated for the first time that he could “reprogram” human skin cells into cells that function like embryonic stem cells, meaning they can multiply indefinitely and transform into any cell type in the body. These reprogrammed cells are known as induced pluripotent stem cells, or iPS cells.
Yamanaka was awarded the 2012 Nobel Prize in Physiology or Medicine for this breakthrough. His discovery fundamentally changed biomedical research and opened up promising avenues for studying and treating unsolved diseases.
Fifteen years later, researchers at Gladstone—and all around the world—continue to use iPS cells to study the cause of disease, test potential drugs, and develop new treatment options. Four scientists explain the power of iPS cells in research.
In the lab, I’m investigating the underlying causes of congenital heart defects, which are a group of heart diseases that affect roughly 1 in 100 live births. I’m using iPS cells, which I can turn into heart cells that beat in the dish—this is so incredible to watch.
I’m using iPS cells, which I can turn into heart cells that beat in the dish—this is so incredible to watch.
This has also revolutionized the way that I can do my research because I can work on human cells that haven’t come from rare patient samples, I can make and correct mutations, and I can generate the enormous number of cells that I need to understand the molecular mechanisms that underlie congenital heart defects.
The groundbreaking invention of induced pluripotent stem cells by Shinya Yamanaka not only gave hope to patients suffering from incurable diseases, but also laid a foundation for scientists to find treatments for the diseases that were considered untreatable before iPS cells.
IPS cells have given direction, acceleration, and meaning to my work in this new era of medical research.
The remarkable thing about this technology is that we collect only 1–5 milliliters of blood from patients, and we reprogram these blood cells to iPS cells, and then generate an unlimited number of mature, somatic cells (such as heart cells or brain cells) for disease modeling and drug discovery in a dish. IPS cells have given direction, acceleration, and meaning to my work in this new era of medical research.
I think one of the often overlooked benefits of iPS cells is the number of animal lives they save. Rodents and other animals have long been used as model systems, and I feel like many people forget about the debt we owe to research animals.
Using iPS cells can significantly reduce the number of animals that give their lives to scientific progress.
So many scientific breakthroughs have come from using animal model systems, and while I recognize their importance in research, using iPS cells can significantly reduce the number of animals that give their lives to scientific progress.
IPS cells are very cool, because they can generate any cell type that’s found in the body. However, one specific cell type that’s remained elusive is the human oocyte, or the egg.
IPS cells are very cool, because they can generate any cell type that’s found in the body.
My research focuses on using iPS cells to generate a very special type of cell, called a primordial germ cell. These cells are the direct stem cell precursors of oocytes. So if we can unlock this final step and actually mature primordial germ cells into oocytes, we could treat infertility and use these iPS cell–derived oocytes for in vitro fertilization.
Watch Juan Carlos Izpisua Belmonte present his award-winning work during the 2022 Ogawa-Yamanaka Stem Cell Prize CeremonyOgawa Stem Cell Prize Stem Cells/iPSCs
Juan Carlos Izpisua Belmonte, recipient of the 2022 Ogawa-Yamanaka Stem Cell Prize, is turning back the clock on old and sick cells, with many potential benefitsAwards Ogawa Stem Cell Prize Profile Stem Cells/iPSCs
Izpisua Belmonte is recognized for his innovative work in programming cellular rejuvenationAwards Institutional News News Release Ogawa Stem Cell Prize Stem Cells/iPSCs